Aton's Stock Soars Nearly 32% Following Announcement
The stock of the Alsatian biotech company surges during the session, following the announcement of the planned European rollout of its oncology-focused molecular analysis platform. This movement extends a trajectory already marked by a significant rebound over three months.
European Rollout of Pims Platform Propels Stock During Session
Aton's stock surged by 31.91% to €0.0124 in early afternoon trading, following the presentation of its subsidiary Pims Technology and its molecular analysis platform aimed at early identification of patients responsive to cancer treatments. On June 25, the group began discussions with European cancer centers for an implementation starting in 2026. This news has reignited speculative interest in this very small capitalization issue, with trading volumes responding sharply to any operational signal. This movement contrasts with a CAC 40 down by 0.81% and an SBF 120 in the red, further isolating the stock's performance.
A Rebound that is Part of a Fundamental Uptrend Over Three Months
The session extends a fundamental dynamic: Aton has risen by 116.7% over three months and 58.54% over a year, with the price moving above its 20, 50, and 200-day moving averages. However, the RSI at 37 remains in a low zone, indicating that the stock was coming off a breathing phase before today's surge. It is worth recalling that the end of April financial statements reported a reduction in losses but also equity brought down to €0.4 million, a point of financial vulnerability that contextualizes the high volatility of the issue (41.46% monthly volatility). The next important date on the schedule is the annual general meeting planned for June 30, 2026.
